I am very excited to share with you an article by BizNews Editor Jackie Cameron which was featured in their “Thought Leaders” segment. I urge you to read or listen to my interview here: Major Tech Breakthrough in Human Application, as Scientists Aim to Save The World From COVID-19 and Malaria.
 
The team here at Mountain Valley was thrilled with Cameron’s take on the company and our mission to change the world for the better.  It also answers for the first time the revenue question of Ivermectin and if the world could see MVMD’s solubilized format this year, are we pursuing human trials and will we pursue a pathway with the FDA.  Spoiler alert… “Absolutely”.
 
BizNews has hubs in London, Johannesburg and Cape Town, and is uniquely positioned to serve South Africans with a global mindset through independent reporting and commentary on local and global issues that affect their lives.
 
Of course, in South Africa, Ivermectin has been in the news and at the centre of the public dialogue around COVID-19, as their Health Products Regulatory Authority approved “compassionate access” to Ivermectin in the treatment of COVID-19 under a special, controlled authorization. Front line doctors led the charge for Ivermectin’s approval and have since taken the government to court for even quicker access.
 
And as you have seen, there is a mountain of evidence globally around the effectiveness of Ivermectin as a therapeutic for COVID-19. 
 
With our BSL-4 lab trials commencing in just a few short weeks, we are not resting there by any means.  We are aggressively moving in parallel to include our solubilized Ivermectin in human trials and pursuing a 505(b)(2) pathway with the U.S. Food and Drug Administration (FDA) based on the overwhelming safety and efficacy data on the Ivermectin drug.
 
I hope you can check out the article, but in the meantime, here are a few key quotes that give you a taste of the interview…
 
On Mountain Valley MD:
 
“Our company has some technology that simply takes world class drugs and makes them more effective. Some of the latest breakthroughs that we have include a solubilisation of Ivermectin. Ivermectin is a broad therapeutic that’s starting to get a lot of traction with COVID-19, as a therapeutic. What we’ve been able to do is take a very insolubilised drug and make it incredibly solubilised. In this particular case, the viscosity of water.”
 
On World’s First:
 
“Our solubilised Ivermectin is the first of its kind in the world. Essentially what we’ve done is taken a very poorly soluble drug and made it 5,000 times more soluble. What does that mean? Well, now we’re able to lay it into some of our rapid dissolve technologies. So imagine just a little, Chicklets sized piece of gum, if you will, that goes in your mouth and dissolves in under 30 seconds.
 
It requires no water. You don’t have to swallow the pill. Then we also have an injectable form of that soluble Ivermectin – which today there’s no FDA approved injectable form of Ivermectin, because they require harmful organic solvents in that mix. Our patented technique requires two excipients that are already approved by the FDA. So it becomes a leading candidate for injectable Ivermectin.”
 
 
On whether the world will see MVMD’s solubilized Ivermectin this year:
 
“Absolutely. So somewhere like Africa as well, they would be much more acceptable to the current safety data as well. I don’t want to say just because they have lower thresholds, but candidly, the FDA and work in Canada – they’re just more difficult markets, very litigious environments.
 
All of that stuff is more complex. There’s no doubt that the solubilisation technique that we have, could easily come to market within a time frame that you’re suggesting. We could apply for emergency use authorisation with very senior health leaders inside of Africa.”
 
 
There are so many exciting things we are working on and as you know our team continues to move at warp speed while the world is waking up to just how big of an impact Mountain Valley MD’s technology can have in dramatically impacting human and animal health globally.
 
Thanks as always to our shareholders and supporters for being such an integral part of our journey.
 

Regards,
 
Dennis